Treosulfan was approved by the FDA for medical use on 04/08/2015 as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Treosulfant is an anti-neoplastic medication belonging to the group called alkylating agents. This medicine is combined with Fludarabine to treat allogeneic hemopoietic stem cell transplant (alloHSCT) in adults with both malignant and non-malignant. In pediatric patients (older than one month), it treats malignant. 

Treosulfan injection is administered as an intravenous infusion into the vein. If this injection is recommended for you, it will be given by a healthcare professional. Do not self-administer. Your physician will choose the dosage and administration frequency based on the medical condition because it differs for each person.

The most common side effects of Treosulfan are diarrhea, constipation, weight loss, poor appetite, nausea, vomiting, excessive growth of hair in the skin, low blood counts, difficulty breathing, cough, liver problems, infections, headache, weakness, and skin rash. 

Serious side effects while taking Treosulfan are decreased blood cell count, infections, liver vein blockage, and lung inflammation.

Do not take a Treosulfan injection if you are allergic to Treosulfan or its other ingredients. Notify your doctor if you have any infections or disorders with the heart, lungs, liver, or kidney. Before starting the treatment, inform your doctor if you took any live vaccine or have Fanconi anemia (inherited bone marrow failure syndromes) or other DNA breakage repair disorders. 

This medicine may reduce the blood count (myelosuppression); your doctor will monitor your blood counts and liver enzymes regularly to detect their functions until recovery of the hematopoietic system. Before taking a Treosulfan injection, notify your doctor if you are pregnant or planning to get pregnant or breastfeeding. In pediatric patients, dermatitis diaper (inflammation of the skin in the diaper area) may occur, so napkins should be changed frequently for 6–8 hours. Contact your doctor for more information. 

Store at 25˚C, excursions permitted to 15˚C to 30˚C. Keep away from pets and children. Do not refrigerate. This medicine can cause fertility impairment; consult your doctor for more fertility concerns. Don't splash or spill the medicine anywhere on the skin. In infants under four months, there is a chance of getting a seizure. Hence monitor for nervous disorders and breathing problems. 

1. Medexus Inc., [Revised on 25th Jun 2021] [Accessed on 06 May 2023], https://d1io3yog0oux5.cloudfront.net/medexusinc/files/pages/medexusinc/db/795/description/Trecondyv+Product+Monograph.pdf
2. Medac,  [Accessed on 06 May 2023], https://www.ema.europa.eu/en/documents/product-information/trecondi-epar-product-information_en.pdf
3. International Agency for Research on Cancer; Treosulfan; PHARMACEUTICALS; NCBI Bookshelf; [Revised on 2012] [Accessed:06 May 2023]; https://www.ncbi.nlm.nih.gov/books/NBK304322/#_NBK304322_pubdet_
4. RA Hilger et al.; Clinical pharmacokinetics of intravenous Treosulfan in patients with advanced solid tumors; [Revised on 1998] [Accessed:06 May 2023] ; https://pubmed.ncbi.nlm.nih.gov/9654108/
5. GP Breitbach; Treosulfan in the treatment of advanced ovarian cancer: a randomized co-operative multicentre phase-III study; [Revised on 2002] [Accessed:06 May 2023]; https://pubmed.ncbi.nlm.nih.gov/12530019/

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.